Impact of Biweekly and Triweekly Dosing Regimens on Progression-Free Survival in First-Line FOLFIRI Treatment of Metastatic Colorectal Cancer: A Non-Inferiority Study (FIR-DIR)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522305-38-00

Enrollment

Registered

2025-07-18

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic colorectal cancer

Brief summary

Progression-Free Survival (PFS) assessed by the investigators

Detailed description

Overall Survival (OS) data in both treatment arms, Time on treatment (ToT) periods in both treatment arms, AE, SAE events by CTCAE v.5.

Interventions

DRUGIRINOTECAN

DRUGCALCIUM FOLINATE

DRUGFLUOROURACIL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival (PFS) assessed by the investigators	—

Secondary

Measure	Time frame
Overall Survival (OS) data in both treatment arms, Time on treatment (ToT) periods in both treatment arms, AE, SAE events by CTCAE v.5.	—

Countries

Hungary

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026